Related Experiment Video

Updated: May 26, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells

Katarzyna Krzykowska-Petitjean1, Jędrzej Małecki, Anna Bentke

  • 1Jagiellonian University Medical College, ul. Kopernika 7, 31-034 Kraków, Poland.

Journal of Cancer Research and Clinical Oncology
|January 3, 2012
PubMed
Abstract

Insights

Combining tipifarnib (R115777) with LY294002 or tanespimycin (17AAG) significantly reduced cancer cell numbers and induced apoptosis in U937 cells. These combinations show promise for treating hematological malignancies.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Tipifarnib (R115777), a farnesyltransferase inhibitor, has limited anticancer effects in hematological malignancies.
  • Research is ongoing to find synergistic agents to enhance R115777's efficacy.
  • PI-3 kinase inhibitor LY294002 and Hsp90 inhibitor tanespimycin (17AAG) were investigated for combination therapy.

Purpose of the Study:

  • To evaluate the synergistic anticancer effects of combining R115777 with LY294002 or 17AAG.
  • To assess the impact of these drug combinations on cancer cell viability and apoptosis.
  • To determine the potential of combination therapy in treating hematological malignancies.

Main Methods:

  • Experiments were conducted using U937 cells, a model for liquid tumors.
  • Cell viability was assessed using trypan blue staining.
  • Apoptosis was measured by quantifying active caspase-3 and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL).

Main Results:

  • Individual drugs at tested concentrations only slowed proliferation.
  • The combination of R115777 + LY294002 significantly reduced cell number and induced apoptosis.
  • The combination of R115777 + 17AAG also significantly reduced cell number and induced apoptosis.

Conclusions:

  • Combination therapy with R115777 and 17AAG demonstrates significant anti-cancer activity.
  • These findings suggest potential clinical utility of the R115777 + 17AAG combination for hematological malignancies.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...